Use of rivaroxaban in Germany: A database drug utilization study of a drug started in hospital

European Journal of Clinical Pharmacology

Volumn 70, Issue 8, 2014, Pages 975-981

  Jobski, Kathrin ^a   Enders, Dirk ^a   Amann, Ute ^b,c   Suzart, Kiliana ^d   Wallander, Mari Ann ^e   Schink, Tania ^a   Garbe, Edeltraut ^a,f  

^a LEIBNIZ INSTITUTE FOR PREVENTION RESEARCH AND EPIDEMIOLOGY BIPS   (Germany)

^b KLINIKUM AUGSBURG   (Germany)

^c INSTITUTE OF EPIDEMIOLOGY   (Germany)

^d BAYER PHARMA AG   (Germany)

^e UPPSALA UNIVERSITY   (Sweden)

^f UNIVERSITY OF BREMEN   (Germany)

Author keywords

Drug utilization; German Pharmacoepidemiological Research Database; Inpatient drug use; Rivaroxaban

Indexed keywords

BLOOD CLOTTING FACTOR 10A INHIBITOR; MORPHOLINE DERIVATIVE; RIVAROXABAN; THIOPHENE DERIVATIVE;

ADOLESCENT; ADULT; AGED; DRUG UTILIZATION; FACTUAL DATABASE; FEMALE; GERMANY; HIP ARTHROPLASTY; HOSPITAL; HUMAN; KNEE ARTHROPLASTY; MALE; MIDDLE AGED; OFF LABEL DRUG USE; STATISTICS AND NUMERICAL DATA; VENOUS THROMBOEMBOLISM; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ARTHROPLASTY, REPLACEMENT, HIP; ARTHROPLASTY, REPLACEMENT, KNEE; DATABASES, FACTUAL; DRUG UTILIZATION; FACTOR XA INHIBITORS; FEMALE; GERMANY; HOSPITALS; HUMANS; MALE; MIDDLE AGED; MORPHOLINES; OFF-LABEL USE; THIOPHENES; VENOUS THROMBOEMBOLISM; YOUNG ADULT;

EID: 84905098343     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-014-1697-7     Document Type: Article

References (20)

1. Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e.V.(AWMF) (2010) S3-Leitlinie Prophylaxe der venösen Thromboembolie (VTE)
2. Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, Colwell CW (2008) Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133(6 Suppl):381S-453S (Pubitemid 351894916)
3. Selby R, Borah BJ, McDonald HP, Henk HJ, Crowther M, Wells PS (2012) Impact of thromboprophylaxis guidelines on clinical outcomes following total hip and total knee replacement. Thromb Res 130(2):166-172
4. Friedman RJ (2010) Simplifying thromboprophylaxis could improve outcomes in orthopaedic surgery. Thrombosis 2010, 108049
5. European Medicines Agency (EMA) (2008) Xarelto: EPAR-public assessment report (CHMP Assessment Report for Xarelto, INN: Rivaroxaban)
6. European Medicines Agency (EMA) (2012) Xarelto: EPAR-Summary for the public. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Product- Information/human/000944/WC500057108.pdf
7. Bayer Schering Pharma AG (2010) Fachinformation Xarelto 10 mg Filmtabletten
8. European Medicines Agency (EMA) (2012) Guideline on good pharmacovigilance practices (GVP) Module VIII-Post-authorisation safety studies. http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2012/ 02/WC500123204.pdf
9. Schneeweiss S, Avorn J (2005) A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol 58(4):323-337 (Pubitemid 40601980)
10. Mikolajczyk RT, Kraut AA, Garbe E (2013) Evaluation of pregnancy outcome records in the German Pharmacoepidemiological Research Database (GePaRD). Pharmacoepidemiol Drug Saf 22(8):873-880
11. Flockhart DA (2011) Drug interactions: cytochrome P450 drug interaction table. Indiana University School of Medicine http://medicine.iupui.edu/ clinpharm/ddis/table.aspx. Accessed 13 Jul 2011
12. Barmer GEK (2012) Report Krankenhaus 2010, Schwerpunktthema: Trends in der Endoprothetik des Hüft- und Kniegelenks. http://www.barmer-gek.de/ barmer/web/Portale/Versicherte/Komponenten/gemeinsame--PDF--Dokumente/Reports/ Report-20Krankenhaus-202010,property=Data.pdf. Accessed 14 Aug 2012
13. Apothekengesetz (Pharmacy Act) (2013) §14 Abs. 7. http://www.gesetze-im-internet.de/apog/BJNR006970960.html
14. Rote Liste (2009) Antikoagulantia. Rote Liste 2009
15. Warwick D, Friedman RJ, Agnelli G, Gil-Garay E, Johnson K, FitzGerald G, Turibio FM (2007) Insufficient duration of venous thromboembolism prophylaxis after total hip or knee replacement when compared with the time course of thromboembolic events: findings from the Global Orthopaedic Registry. J Bone Joint Surg (Br) 89(6):799-807 (Pubitemid 47180202)
16. Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e.V.(AWMF) (2009) S3-Leitlinie Behandlung akuter perioperativer und posttraumatischer Schmerzen. http://www.awmf.org/uploads/tx- szleitlinien/041-001-S3-Behandlung-akuter-perioperativer-und-posttraumatischer- Schmerzen-aktualisierte-Fassung-04-2009-05-2011.pdf
17. Penning-van Beest FJ, Overbeek JA, Meijer WM, Woodruff K, Jackson J, van der Vis H, van der Linden P, Herings RM (2011) Venous thromboembolismprophylaxis after total knee or hip replacement: treatment pattern and outcomes. Pharmacoepidemiol Drug Saf 20(9):972-978
18. Eriksson BI, Rosencher N, Friedman RJ, Homering M, Dahl OE (2012) Concomitant use of medication with antiplatelet effects in patients receiving either rivaroxaban or enoxaparin after total hip or knee arthroplasty. Thromb Res 130(2):147-151
19. Pigeot I, Ahrens W (2008) Establishment of a pharmacoepidemiological database in Germany: methodological potential, scientific value and practical limitations. Pharmacoepidemiol Drug Saf 17(3):215-223 (Pubitemid 351404032)
20. Zotz RB, Kauschat-Bruning D, Bramlage P (2009) Thromboembolic risk and prophylaxis in hospitalized surgical and internal medicine patients. German results of the international ENDORSE study. Dtsch Med Wochenschr 134(43):2163-2169